REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its adeno-associated virus (AAV) delivery platform for a range of diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Louis Bacon / Moore | 55 | Added +33% | 200,000 | $2,880,000 | 0.0% |
| Ancora | 38 | Holds (flat) | 1,000 | $14,400 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.